Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
December 17, 2024 06:00 ET
|
Kynexis
KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1...
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
November 05, 2024 07:30 ET
|
Minerva Neurosciences, Inc
Minerva Neurosciences (Nasdaq: NERV) today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight
October 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight The rise in research and development activities in...
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 06, 2024 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
May 29, 2024 07:00 ET
|
Kynexis
NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain...
The BC Schizophrenia Society Calls on British Columbians to #StandAgainstStigma this National Schizophrenia and Psychosis Awareness Day
May 24, 2024 10:00 ET
|
BC Schizophrenia Society
VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- The British Columbia Schizophrenia Society (BCSS), a provincial non-profit organization dedicated to supporting individuals and families...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
May 01, 2024 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
April 16, 2024 02:30 ET
|
Nxera Pharma
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion of...
Anorexia Nervosa Treatment Advances with New 2024 Pipeline Landscape Report
February 27, 2024 11:06 ET
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Anorexia Nervosa - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A Comprehensive Overview of Emerging...
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
January 04, 2024 06:30 ET
|
Kynexis
KYN-5356 is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathwayTopline results are expected in the second half of 2024 NAARDEN, The Netherlands,...